IMMUTEP LTD-SP ADR (IMMP) Stock Price, Quote, News and Overview
NASDAQ:IMMP - Nasdaq - US45257L1089 - ADR - Currency: USD
IMMP Quote, Performance and Key Statistics
1.51
-0.03 (-1.95%)
The current stock price of IMMP is 1.51 USD. In the past month the price decreased by -19.68%. In the past year, price decreased by -43.02%.
IMMP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About IMMP
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Company Info
IMMUTEP LTD-SP ADR
Level 32, Suite 32.07 Australia Square, 264 George Street
Sydney NEW SOUTH WALES 2000 AU
CEO: Marc Voigt
Employees: 31
Company Website: https://www.immutep.com/
Investor Relations: http://www.immutep.com/investors-media/whats-new.html
Phone: 61283157003
IMMUTEP LTD-SP ADR / IMMP FAQ
What is the stock price of IMMUTEP LTD-SP ADR today?
The current stock price of IMMP is 1.51 USD. The price decreased by -1.95% in the last trading session.
What is the ticker symbol for IMMUTEP LTD-SP ADR stock?
The exchange symbol of IMMUTEP LTD-SP ADR is IMMP and it is listed on the Nasdaq exchange.
On which exchange is IMMP stock listed?
IMMP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUTEP LTD-SP ADR stock?
9 analysts have analysed IMMP and the average price target is 2.35 USD. This implies a price increase of 55.61% is expected in the next year compared to the current price of 1.51. Check the IMMUTEP LTD-SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUTEP LTD-SP ADR worth?
IMMUTEP LTD-SP ADR (IMMP) has a market capitalization of 219.64M USD. This makes IMMP a Micro Cap stock.
How many employees does IMMUTEP LTD-SP ADR have?
IMMUTEP LTD-SP ADR (IMMP) currently has 31 employees.
What are the support and resistance levels for IMMUTEP LTD-SP ADR (IMMP) stock?
IMMUTEP LTD-SP ADR (IMMP) has a resistance level at 1.55. Check the full technical report for a detailed analysis of IMMP support and resistance levels.
Is IMMUTEP LTD-SP ADR (IMMP) expected to grow?
The Revenue of IMMUTEP LTD-SP ADR (IMMP) is expected to decline by -36.07% in the next year. Check the estimates tab for more information on the IMMP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUTEP LTD-SP ADR (IMMP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMMP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMMP, evaluating the profitability, health, valuation and growth aspects
- IMMUTEP LTD-SP ADR (IMMP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUTEP LTD-SP ADR (IMMP) Sales and EPS estimates to see what analysts future expectations are.
- IMMUTEP LTD-SP ADR (IMMP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUTEP LTD-SP ADR (IMMP) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUTEP LTD-SP ADR (IMMP) Stock Chart to make your own analysis
- IMMUTEP LTD-SP ADR (IMMP) Latest news and press-releases to stay up to date.
Does IMMUTEP LTD-SP ADR (IMMP) stock pay dividends?
IMMP does not pay a dividend.
When does IMMUTEP LTD-SP ADR (IMMP) report earnings?
IMMUTEP LTD-SP ADR (IMMP) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of IMMUTEP LTD-SP ADR (IMMP)?
IMMUTEP LTD-SP ADR (IMMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
What is the Short Interest ratio of IMMUTEP LTD-SP ADR (IMMP) stock?
The outstanding short interest for IMMUTEP LTD-SP ADR (IMMP) is 3.57% of its float. Check the ownership tab for more information on the IMMP short interest.
IMMP Technical Analysis
IMMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMP. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMMP Financial Highlights
Over the last trailing twelve months IMMP reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 14.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| Debt/Equity | 0 |
IMMP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IMMP. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -18.98% and a revenue growth -36.07% for IMMP